Angion Biomedica Corp
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $19.53 million
- Book Value:
- Revenue TTM:
- $28.24 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Angion Biomedica Corp had its IPO on 2021-02-05 under the ticker symbol ANGN.
The company operates in the Healthcare sector and Biotechnology industry. Angion Biomedica Corp has a staff strength of 71 employees.
Shares of Angion Biomedica Corp opened at $10.6 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $8.9 - $10.6, and closed at $10.
This is a +2.04% increase from the previous day's closing price.
A total volume of 224,845 shares were traded at the close of the day’s session.
In the last one week, shares of Angion Biomedica Corp have increased by +19.23%.
Angion Biomedica Corp's Key Ratios
Angion Biomedica Corp has a market cap of $19.53 million, indicating a price to book ratio of 0.4859 and a price to sales ratio of 0.8958.
In the last 12-months Angion Biomedica Corp’s revenue was $28.24 million with a gross profit of $-20819000 and an EBITDA of $-11718000. The EBITDA ratio measures Angion Biomedica Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Angion Biomedica Corp’s operating margin was -42.13% while its return on assets stood at -8.68% with a return of equity of -30.47%.
In Q3, Angion Biomedica Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 20.9%.
Angion Biomedica Corp’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Angion Biomedica Corp’s profitability.
Angion Biomedica Corp stock is trading at a EV to sales ratio of 2.2573 and a EV to EBITDA ratio of 2.4526. Its price to sales ratio in the trailing 12-months stood at 0.8958.
Angion Biomedica Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $61.32 million
- Total Liabilities
- $8.18 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Angion Biomedica Corp ended 2023 with $61.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $61.32 million while shareholder equity stood at $50.21 million.
Angion Biomedica Corp ended 2023 with $0 in deferred long-term liabilities, $8.18 million in other current liabilities, 301000.00 in common stock, $-247502000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $55.14 million and cash and short-term investments were $55.14 million. The company’s total short-term debt was $1,032,000 while long-term debt stood at $0.
Angion Biomedica Corp’s total current assets stands at $56.68 million while long-term investments were $874000.00 and short-term investments were $0. Its net receivables were $7000.00 compared to accounts payable of $2.22 million and inventory worth $0.
In 2023, Angion Biomedica Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Angion Biomedica Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Angion Biomedica Corp stock is currently trading at $10 per share. It touched a 52-week high of $2.625 and a 52-week low of $2.625. Analysts tracking the stock have a 12-month average target price of $1.5.
Its 50-day moving average was $7.08 and 200-day moving average was $8.18 The short ratio stood at 0.68 indicating a short percent outstanding of 0%.
Around 3301.5% of the company’s stock are held by insiders while 1635.5% are held by institutions.
Frequently Asked Questions About Angion Biomedica Corp
Similar Industry Stocks (Biotechnology)
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.